BC Partners agrees to sell Pharmathen to Partners Group. The advisors

International investment firm BC Partners announced the sale of Pharmathen, a Greece-based pharmaceutical company, to global private markets firm Partners Group (acting on behalf of its clients). The transaction values Pharmathen at an enterprise value of around EUR 1.6 billion. The deal, which is subject to receipt of customary regulatory approvals, is expected to close in 2021.

Pharmathen was founded in 1969 and acquired by funds advised by BC Partners in 2015 for €475 million. Partners Group will work closely with Pharmathen’s management team, led by CEO Dimitris Kadis.

The advisors

For BC Partners, in-house general counsel Jason Schaefer (pictured) acted as legal counsel alongside Kirkland & Ellis law firm. Jefferies acted as financial advisors while Pwc provided accounting advice and services.

For Partners Group Holding, Swiss-based in-house general counsel Andreas Knecht acted as legal counsel. Alongside U.S. based Ropes & Gray law firm. EY acted as accountants on this transaction.

BC Partners

Established in 1986, BC Partners is an international investment firm with over €33 billion of assets under management in private equity, private credit and real estate strategies. The firm operates out of offices in North America and Europe. Since inception, BC Partners has completed 123 private equity investments in companies with a total enterprise value of over €161 billion and is currently investing its eleventh private equity fund.

For further details on the deal click here